Vertex Pharmaceuticals, Inc.

Sarah Robertson

Weichao George Chen

Samuel Moskowitz

Eric L Haseltine

David Waltz

Eleni Dokou

Varsha Dhamankar

Beili Zhang

Lori Ann Ferris

Kirk Raymond Dinehart

Katie McCarty

Nishanth Gopinathan

Catherine Metzler

Mark Willem Ledeboer

Ales Medek

Valdas Jurkauskas

Yi Shi

Michael Waldo

Praveen Mudunuri

Randal Byrn

Kwame Wiredu Nti-Addae

Steven Jones

Mohammed Asmal

Simon Adam O'Neil

John Gregg Van Alsten

Wanjung Tsai

Cathy Chu

Dainius Macikenas

Katie Mccarty

Welchao George Chen

Compound I of the formula and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

Methods of treatment for cystic fibrosis

Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis. 

Compound I of the formula (formula) A pharmaceutically acceptable salt of Compound I. Pharmaceutical compositions containing at least Compound I and methods of treating cystic fibrosis comprising administering at least Compound I. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound I. 

A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.

Pharmaceutical compositions for treating cystic fibrosis

Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Crystalline forms and compositions of CFTR modulators

Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).&#xbd;HO, Form F of HCl salt of Compound (1).3HO, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.

Inhibitors of influenza viruses replication

Growing community of inventors

Somerville, MA, United States of America

Sarah Robertson